Adnectins: Engineered Target-binding Protein Therapeutics

Overview

Journal Protein Eng Des Sel

Publisher Oxford University Press

Specialties Biochemistry
Biotechnology

Date 2010 Nov 12

PMID 21068165

Citations 92

Authors

D Lipovsek

Affiliations

Soon will be listed here.

Abstract

Adnectins™ are a new family of therapeutic proteins based on the 10th fibronectin type III domain, and designed to bind with high affinity and specificity to therapeutically relevant targets. Adnectins share with antibody variable domains a beta-sheet sandwich fold with diversified loops, but differ from antibodies in primary sequence and have a simpler, single-domain structure without disulfide bonds. As a consequence, Adnectins bind targets with affinity and specificity as high as those of antibodies, but are easier to manipulate genetically and compatible with bacterial expression systems. Adnectins that bind macromolecular targets with nanomolar and picomolar affinity have been selected using in vitro evolution methods, including mRNA display, phage display and yeast display. CT-322, a PEGylated, anti-angiogenic Adnectin that binds vascular endothelial growth factor (VEGF) receptor 2 and blocks its interaction with VEGF A, C and D, is being evaluated in Phase II clinical trials for efficacy in several oncology indications.

Citing Articles

Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies.

Paryani M, Gupta N, Jain S, Butani S Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39883121 DOI: 10.1007/s00210-025-03826-4.

Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets.

Colas K, Bindl D, Suga H Chem Rev. 2024; 124(21):12213-12241.

PMID: 39451037 PMC: 11565579. DOI: 10.1021/acs.chemrev.4c00422.

Improving the diffraction quality of heat-shock protein 47 crystals.

Kish K, Cobell S, Szapiel N, Yan C, Newitt J, Tredup J Acta Crystallogr F Struct Biol Commun. 2024; 80(Pt 11):302-313.

PMID: 39397789 PMC: 11533366. DOI: 10.1107/S2053230X24009233.

Ubiquitin-derived artificial binding proteins targeting oncofetal fibronectin reveal scaffold plasticity by β-strand slippage.

Katzschmann A, Haupts U, Reimann A, Settele F, Gloser-Braunig M, Fiedler E Commun Biol. 2024; 7(1):907.

PMID: 39068227 PMC: 11283464. DOI: 10.1038/s42003-024-06569-9.

Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.

Badenhorst M, Windhorst A, Beaino W Front Med (Lausanne). 2024; 11:1401515.

PMID: 38915766 PMC: 11195831. DOI: 10.3389/fmed.2024.1401515.

References

Hackel B, Ackerman M, Howland S, Wittrup K . Stability and CDR composition biases enrich binder functionality landscapes. J Mol Biol. 2010; 401(1):84-96. PMC: 3927142. DOI: 10.1016/j.jmb.2010.06.004. View

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

Fellouse F, Li B, Compaan D, Peden A, Hymowitz S, Sidhu S . Molecular recognition by a binary code. J Mol Biol. 2005; 348(5):1153-62. DOI: 10.1016/j.jmb.2005.03.041. View

Groves M, Osbourn J . Applications of ribosome display to antibody drug discovery. Expert Opin Biol Ther. 2005; 5(1):125-35. DOI: 10.1517/14712598.5.1.125. View

Huston J, Tai M, McCartney J, Warren F, Haber E, Oppermann H . Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 1991; 203:46-88. DOI: 10.1016/0076-6879(91)03005-2. View

Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett K, Barkinge J . A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat Struct Mol Biol. 2010; 17(4):519-27. PMC: 2926940. DOI: 10.1038/nsmb.1793. View

Parker M, Chen Y, Danehy F, Dufu K, Ekstrom J, Getmanova E . Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel. 2005; 18(9):435-44. DOI: 10.1093/protein/gzi050. View

Koide A, Gilbreth R, Esaki K, Tereshko V, Koide S . High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A. 2007; 104(16):6632-7. PMC: 1871837. DOI: 10.1073/pnas.0700149104. View

Mamluk R, Carvajal I, Morse B, Wong H, Abramowitz J, Aslanian S . Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. MAbs. 2010; 2(2):199-208. PMC: 2840239. DOI: 10.4161/mabs.2.2.11304. View

10.

Holt L, Basran A, Jones K, Chorlton J, Jespers L, Brewis N . Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel. 2008; 21(5):283-8. DOI: 10.1093/protein/gzm067. View

11.

Fellouse F, Wiesmann C, Sidhu S . Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci U S A. 2004; 101(34):12467-72. PMC: 515084. DOI: 10.1073/pnas.0401786101. View

12.

Gebauer M, Skerra A . Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009; 13(3):245-55. DOI: 10.1016/j.cbpa.2009.04.627. View

13.

Bloom L, Calabro V . FN3: a new protein scaffold reaches the clinic. Drug Discov Today. 2009; 14(19-20):949-55. DOI: 10.1016/j.drudis.2009.06.007. View

14.

De Groot A, McMurry J, Moise L . Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol. 2008; 8(5):620-6. DOI: 10.1016/j.coph.2008.08.002. View

15.

Karatan E, Merguerian M, Han Z, Scholle M, Koide S, Kay B . Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem Biol. 2004; 11(6):835-44. DOI: 10.1016/j.chembiol.2004.04.009. View

16.

Holt L, Herring C, Jespers L, Woolven B, Tomlinson I . Domain antibodies: proteins for therapy. Trends Biotechnol. 2003; 21(11):484-90. DOI: 10.1016/j.tibtech.2003.08.007. View

17.

Olson C, Roberts R . Design, expression, and stability of a diverse protein library based on the human fibronectin type III domain. Protein Sci. 2007; 16(3):476-84. PMC: 2203324. DOI: 10.1110/ps.062498407. View

18.

Harris L, Skaletsky E, McPherson A . Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol. 1998; 275(5):861-72. DOI: 10.1006/jmbi.1997.1508. View

19.

Liao H, Olson C, Hwang S, Deng H, Wong E, Baric R . mRNA display design of fibronectin-based intrabodies that detect and inhibit severe acute respiratory syndrome coronavirus nucleocapsid protein. J Biol Chem. 2009; 284(26):17512-20. PMC: 2719390. DOI: 10.1074/jbc.M901547200. View

20.

Lipovsek D, Lippow S, Hackel B, Gregson M, Cheng P, Kapila A . Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol. 2007; 368(4):1024-41. DOI: 10.1016/j.jmb.2007.02.029. View